Stock listing

NASDAQ:AVBP ArriVent BioPharma, Inc. Stock

Home listing (NASDAQ) of ArriVent BioPharma, Inc.

Follow ArriVent BioPharma, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:AVBP

$10.52 USD -0.38 (-3.5%)

Close on Nov 20, 2026

Past year -47.6% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$10.38 – $11.35 USDNov 20, 2026
Volume
1.05M sharesNov 20, 2026
Market cap
$544.1M USDAt the close on Nov 20, 2026 · price × 51.72M shares outstanding
52-week range
$10.33 – $35.83 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$24.59M USDMedian day 817,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ArriVent BioPharma, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AVBP · Home$10.52 USD-0.38 (-3.5%)1,053,366$10.93$11.35$10.38$10.90Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AVBP · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$10.52-0.38-3.5%$10.93$11.35$10.381,053,366
$10.90+0.21+2.0%$10.42$11.11$10.332,696,657
$10.69-0.87-7.5%$11.57$11.87$10.50863,852
$11.56-1.45-11.1%$12.86$13.14$11.55644,206
$13.01-0.06-0.5%$13.00$13.24$12.59616,140
$13.07-0.435-3.2%$13.55$13.60$12.89793,945
$13.51+0.015+0.1%$13.62$13.91$13.38910,925
$13.49-0.67-4.7%$14.25$15.05$13.21776,294
$14.16+0.52+3.8%$13.86$14.60$13.50905,949
$13.64+1.41+11.5%$12.40$13.88$12.001,400,448
$12.23-1.26-9.3%$13.39$13.50$12.181,101,682
$13.49+0.47+3.6%$13.39$13.57$12.471,624,627
$13.02-0.33-2.5%$13.47$13.94$13.011,226,259
$13.35-1.52-10.2%$14.89$14.98$13.261,237,292
$14.87-1.08-6.8%$15.78$16.17$14.331,194,900
$15.95+0.22+1.4%$15.87$16.42$15.73658,000
$15.73+0.33+2.1%$15.67$15.89$15.20990,000
$15.40+0.04+0.3%$15.45$15.69$15.001,582,000
$15.36-5.64-26.9%$18.14$18.16$14.785,946,900
$21.00+1.80+9.4%$19.00$21.23$18.183,277,900
$19.20+0.08+0.4%$18.93$19.68$18.78843,700
$19.12+0.27+1.4%$19.07$19.44$18.681,489,200
$18.85+0.91+5.1%$17.94$18.98$17.57817,800
$17.94+1.28+7.7%$16.82$18.14$16.731,013,200
$16.66-0.13-0.8%$16.86$17.23$16.491,334,000
$16.79+0.59+3.6%$16.40$16.91$15.97814,900
$16.20+0.11+0.7%$16.06$16.62$15.261,589,100
$16.09-0.37-2.2%$16.28$16.72$15.951,968,300
$16.46-0.27-1.6%$16.57$16.78$16.261,335,400
$16.73+0.02+0.1%$16.59$17.76$16.491,731,100
$16.71-0.18-1.1%$16.62$16.91$15.782,154,200
$16.89+1.80+11.9%$15.25$17.35$14.974,332,600
$15.09-13.37-47.0%$12.09$15.79$11.3619,742,400
$28.46+0.19+0.7%$28.00$28.70$27.02494,800
$28.27-0.66-2.3%$29.26$29.33$27.80507,600
$28.93-1.35-4.5%$29.99$30.64$28.81591,800
$30.28+0.74+2.5%$29.69$30.90$29.65712,500
$29.54+0.24+0.8%$29.30$30.05$28.80780,000
$29.30+0.85+3.0%$28.38$29.90$28.021,016,600
$28.45-1.65-5.5%$30.16$30.55$28.43653,200
$30.10-0.20-0.7%$29.94$30.51$29.24609,000
$30.30-0.02-0.1%$30.32$31.49$29.841,206,000
$30.32+0.58+2.0%$30.22$30.50$29.56389,100
$29.74+0.84+2.9%$29.17$31.16$28.20937,000
$28.90+0.54+1.9%$29.00$29.64$28.621,238,500
$28.36+0.71+2.6%$28.24$28.45$27.84456,400
$27.65-0.32-1.1%$28.15$28.31$27.28379,400
$27.97-0.60-2.1%$28.51$28.75$27.70337,300
$28.57-0.43-1.5%$29.10$29.83$28.40538,300
$29.00+0.30+1.0%$29.16$29.21$28.151,132,000
$28.70-1.09-3.7%$29.33$30.53$28.54564,200
$29.79-0.49-1.6%$30.02$30.26$29.40280,100
$30.28-0.67-2.2%$30.57$31.40$30.02722,000
$30.95-0.08-0.3%$30.79$31.45$30.60182,400
$31.03+0.52+1.7%$30.58$31.39$30.22465,400
$30.51+0.36+1.2%$30.33$30.79$29.60423,900
$30.15+0.10+0.3%$30.10$30.33$29.70356,100
$30.05-0.12-0.4%$29.94$30.26$29.35369,600
$30.17-0.83-2.7%$30.53$31.37$29.75353,500
$31.00-0.14-0.4%$30.79$31.77$30.24300,000
$31.14-0.21-0.7%$31.21$31.41$30.11433,800
$31.35+3.09+10.9%$28.64$31.52$28.64961,653
$28.26-0.86-3.0%$29.02$29.02$28.05225,594
$29.12-0.06-0.2%$29.45$29.77$28.95304,800
$29.18-0.84-2.8%$29.73$29.81$28.64406,300
Ticker
NASDAQ:AVBP
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All ArriVent BioPharma, Inc. news

ArriVent BioPharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
12 in the last 12 months · 34 in all · newest Nov 9, 2026 · oldest 2024
Decks
4 decks · latest August 2026

Where ArriVent BioPharma, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AVBP · Home listing · This pageNASDAQUnited StatesUSD
BOATS:AVBPBOATSUnited StatesUSD

Valuation

EV/sales 30.2× against a median of 44.8×: 3rd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$151.2M USD
P/E
Loss
EV/sales
30.2×
EV/EBITDA
Negative EBITDA
Price/book
1.4×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.18

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ArriVent BioPharma, Inc. · NASDAQ:AVBPUS$544.1MUS$151.2Mn/a30.2×n/a1.4×n/a0.0×1.18
Entera Bio Ltd. · NASDAQ:ENTXUS$574.8MUS$308.9Mn/an/an/a2.1×n/a0.0×0.76
DBV Technologies SA · EURONEXT:DBVUS$571.8MUS$430.7Mn/a47.1×n/a3.9×n/a0.1×n/a
Ascletis Pharma, Inc. · HKEX:1672US$571.3MUS$232.4Mn/a765×n/a1.7×n/a0.0×n/a
4D Molecular Therapeutics, Inc. · NASDAQ:FDMTUS$565.1MUS$277.8Mn/a2.9×n/a1.7×−208.6%0.1×1.75
Bicara Therapeutics Inc. · NASDAQ:BCAXUS$560.3MUS$118.8Mn/an/an/a1.4×n/a0.0×1.37
Lepu Biopharma Co. Ltd. Class H · HKEX:2157US$554.8MUS$613.4M14.6×4.5×22.9×2.6×28.0%0.8×n/a
Aclaris Therapeutics, Inc. · NASDAQ:ACRSUS$545.6MUS$431.3Mn/a67.4×n/a3.3×n/a0.0×1.42
Surrozen, Inc. · NASDAQ:SRZNUS$542.5MUS$448.0Mn/a42.5×n/an/an/an/a1.64
Climb Bio, Inc. · NASDAQ:CLYMUS$539.8MUS$335.4Mn/an/an/a2.4×n/a0.0×1.44
Abbisko Cayman Limited · HKEX:2256US$518.9MUS$228.7Mn/an/an/a1.6×n/a0.2×n/a
Median of the othersUS$557.5MUS$322.2M14.6×44.8×22.9×2.1×−90.3%0.0×1.43

Forecasts

11 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.

Price target
26.10 USD · Analysts' mean
EPS, year to Dec 2026
-4.05 · 9 analysts
Revenue, year to Dec 2026
5M · 5 analysts

Team and board

Officers

OfficerRole
Zhengbin YaoChairman, Chief Executive Officer
Winston KungChief Financial Officer
Robin LaChapelleChief Operating Officer
James KastenmayerGeneral Counsel
Brent RiceChief Commercial Officer
Yang WangChief Technology Officer

Board

DirectorRole
Zhengbin YaoChairman, Chief Executive Officer
Chris NoletDirector
James HealyDirector
John HohnekerDirector
Kristine PetersonLead Independent Director
Merdad ParseyDirector
Stuart LutzkerDirector

Events

Next results
Mar 8, 2027 (expected)
QuarterResultsShare move
Q3 2026Nov 9, 2026 · After close−4.7%
Q2 2026Aug 12, 2026−4.4%
Q1 2026May 11, 2026 · After close−0.2%
Q4 2025Mar 26, 2026−5.8%
Q3 2025Nov 10, 2025 · Before open+3.1%
Q2 2025Aug 11, 2025 · Before open−3.3%
Q1 2025May 12, 2025 · Before open−0.8%
Q4 2024Mar 3, 2025−7.0%
Q3 2024Nov 14, 2024 · Before open−11.9%
Q2 2024Aug 14, 2024 · After close−0.4%
All 12 quarters
QuarterResultsShare move
Q1 2024May 8, 2024 · Before open+0.6%
Q4 2023Mar 28, 2024 · After close+2.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (August 2026)Investor deck21 slidesAugust 2026
Investor Presentation (June 2025)Investor deck25 slidesJun 23, 2025
Technical Presentation (September 2024)Technical13 slidesSep 8, 2024
European Lung Cancer Congress 2022Conference12 slidesMar 18, 2022

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: US$75M · US$19.5 a share · Goldman Sachs & Co. LLC +7
Dealers: Goldman Sachs & Co. LLC (co-lead), Citigroup (co-lead), Guggenheim Securities (co-lead), LifeSci Capital, Oppenheimer & Co., B. Riley Securities, H.C. Wainwright & Co., Jones
Use of proceeds: Support activities for firmonertinib and other pipeline programs, working capital and general corporate purposes
Jul 1, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Jan 25, 2024.

Price
US$18.00 a share
Shares offered
9,722,222 shares of common stock
Offering size
US$175 million
Underwriters' option
Up to 1,458,333 more shares
Listing
AVBP on the Nasdaq Global Market
Underwriters
Goldman Sachs & Co. LLC, Jefferies, Citigroup, LifeSci Capital · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 25, 2023
Filed publiclyJan 5, 2024
Amended twiceNewest Jan 23, 2024
Shares registered with an exchangeJan 23, 2024
Declared effective by the SECJan 25, 2024
Final prospectus, with the priceJan 26, 2024

Open IPO · From the cover of the final prospectus (424B4) filed Jan 26, 2024

Financials

Annual, in USD

Income statement

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Revenue0000
Research and development153.4M153.4M79.0M79.0M64.9M64.9M30.4M6.43M
Selling, general and administrative24.2M15.3M9.71M6.47M3.02M
Operating income-177.5M-177.5M-94.3M-94.3M-74.6M-74.6M-36.9M-8.70M
Depreciation and amortization-3.03M3.03M36.9M11.6M
EBITDA-180.6M-174.5M02.90M
Income before tax-166.3M-80.5M-69.3M-36.9M-51.6M
Income tax-80.5M-36.9M-11.6M
Net income-166.3M-166.3M-80.5M-80.5M-69.3M-69.3M-36.9M-51.6M
Earnings per share, basic-4.32-4.32-2.56-2.56-32.38-2.17-1.10-40.44
Earnings per share, diluted-4.32-2.56-32.38

Balance sheet

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Cash and equivalents45.5M45.5M74.3M74.3M150.4M150.4M163.4M37.3M
Short-term investments267.3M267.3M144.6M144.6M0
Receivables60.0K500.0K761.0K500.0K250.0K
Inventory-240.0K
Current assets332.9M332.9M227.0M227.0M160.0M160.0M182.6M43.0M
Total assets333.2M333.2M274.9M274.9M163.1M163.1M182.8M43.0M
Accounts payable5.93M5.93M3.78M3.78M4.53M4.53M3.09M293.0K
Current liabilities25.9M25.9M17.3M17.3M11.6M11.6M8.36M1.82M
Total debt14.0K176.0K317.0K139.0K
Total liabilities25.9M25.9M17.3M17.3M11.8M11.8M8.37M1.82M
Shareholders' equity307.2M307.2M257.7M257.7M-153.2M151.3M174.5M41.2M
Shares outstanding42.5M38.5M33.7M31.5M2.75M32.0M33.5M1.28M

Cash flow

LineFY2025FY2025FY2024FY2024FY2023FY2023FY2022FY2021
Cash from operations-160.6M-160.6M-70.2M-70.2M-55.8M-55.8M-43.6M-12.6M
Capital spending00000
Free cash flow-160.6M-70.2M-55.8M-43.6M-12.6M
Cash from investing-71.2M-71.2M-192.5M-192.5M-40.0M
Cash from financing203.1M203.1M186.6M186.6M42.9M42.9M169.7M89.9M
Change in cash-28.8M-28.8M-76.1M-76.1M-13.0M-13.0M126.1M37.3M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 9, 2026Quarterly reportSEC
8-K · Current reportNov 9, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2026Big-stake noticeSEC
4 · Change in ownershipNov 2, 2026Insider tradeSEC
8-K · Current reportOct 26, 2026Current reportSEC
8-K · Current reportOct 19, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeOct 13, 2026Big-stake noticeSEC
8-K · Current reportOct 13, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 8, 2026Big-stake noticeSEC
8-K · Current reportOct 6, 2026Current reportSEC
All 162 filings
FilingDateTypeFiled with
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
8-K · Current reportAug 12, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 27, 2026Big-stake noticeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
4 · Change in ownershipJun 22, 2026Insider tradeSEC
8-K · Current reportJun 22, 2026Meeting outcomeSEC
8-K · Current reportMay 11, 2026Current reportSEC
424B5 · ProspectusMay 11, 2026Offer documentSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 28, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2026Meeting noticeSEC
8-K · Current reportMar 17, 2026Current reportSEC
S-8 · Registration statement for employee plansMar 5, 2026Offer documentSEC
10-K · Annual reportMar 5, 2026Annual reportSEC
8-K · Current reportMar 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 5, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 4, 2026Insider tradeSEC
4 · Change in ownershipFeb 3, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 30, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 21, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 30, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 17, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeOct 15, 2025Big-stake noticeSEC
8-K · Current reportSep 9, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
8-K · Current reportAug 11, 2025ResultsSEC
8-K · Current reportJul 21, 2025Current reportSEC
4 · Change in ownershipJul 15, 2025Insider tradeSEC
424B5 · ProspectusJul 2, 2025Offer documentSEC
8-K · Current reportJul 2, 2025Material contractSEC
424B5 · ProspectusJul 1, 2025Offer documentSEC
8-K · Current reportJun 23, 2025Current reportSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
8-K · Current reportJun 20, 2025Meeting outcomeSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
4 · Change in ownershipApr 29, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 29, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 28, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 28, 2025Meeting noticeSEC
8-K · Current reportApr 28, 2025Management or board changeSEC
8-K · Current reportMar 13, 2025Current reportSEC
S-8 · Registration statement for employee plansMar 3, 2025Offer documentSEC
8-K · Current reportMar 3, 2025ResultsSEC
10-K · Annual reportMar 3, 2025Annual reportSEC
SCHEDULE 13G · Big-stake noticeFeb 14, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
4 · Change in ownershipFeb 14, 2025Insider tradeSEC
S-3ASR · Registration statementFeb 3, 2025Offer documentSEC
8-K · Current reportJan 21, 2025Material contractSEC
SC 13G · Big-stake noticeDec 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 24, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 11, 2024Big-stake noticeSEC
4 · Change in ownershipSep 23, 2024Insider tradeSEC
8-K · Current reportSep 9, 2024Current reportSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
8-K/A · Current report, amendedJul 9, 2024Management or board changeSEC
8-K/A · Current report, amendedJul 9, 2024Management or board changeSEC
8-K · Current reportJun 5, 2024Material contractSEC
4 · Change in ownershipMay 20, 2024Insider tradeSEC
3 · Initial statement of ownershipMay 20, 2024Insider tradeSEC
8-K · Current reportMay 16, 2024Management or board changeSEC
10-Q · Quarterly reportMay 8, 2024Quarterly reportSEC
8-K · Current reportMay 8, 2024ResultsSEC
4 · Change in ownershipApr 23, 2024Insider tradeSEC
3 · Initial statement of ownershipApr 23, 2024Insider tradeSEC
8-K · Current reportApr 22, 2024Management or board changeSEC
10-K · Annual reportMar 28, 2024Annual reportSEC
8-K · Current reportMar 28, 2024ResultsSEC
SC 13G · Big-stake noticeFeb 13, 2024Big-stake noticeSEC
SC 13D · Big-stake noticeFeb 5, 2024Big-stake noticeSEC
S-8 · Registration statement for employee plansFeb 2, 2024Offer documentSEC
4 · Change in ownershipFeb 1, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
4 · Change in ownershipJan 31, 2024Insider tradeSEC
8-K · Current reportJan 30, 2024Current reportSEC
SEC STAFF LETTERJan 30, 2024Other filingsSEC
4 · Change in ownershipJan 29, 2024Insider tradeSEC
4 · Change in ownershipJan 29, 2024Insider tradeSEC
424B4 · ProspectusJan 26, 2024Offer documentSEC
EFFECT · Notice that a registration is effectiveJan 26, 2024Other filingsSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
3 · Initial statement of ownershipJan 25, 2024Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringJan 25, 2024Offer documentSEC
CERT · Exchange's certificate of listingJan 25, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 23, 2024Offer documentSEC
8-A12B · Registration of shares for listing on an exchangeJan 23, 2024Other filingsSEC
CORRESP · Letter to the SECJan 23, 2024Other filingsSEC
CORRESP · Letter to the SECJan 23, 2024Other filingsSEC
CORRESP · Letter to the SECJan 22, 2024Other filingsSEC
S-1/A · Registration statement, amendedJan 22, 2024Offer documentSEC
UPLOAD · Letter from the SECJan 12, 2024Other filingsSEC
CORRESP · Letter to the SECJan 11, 2024Other filingsSEC
S-1 · Registration statementJan 5, 2024Offer documentSEC
DRSLTR · Letter to the SEC with a draftDec 5, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedDec 5, 2023Offer documentSEC
UPLOAD · Letter from the SECNov 15, 2023Other filingsSEC
DRSLTR · Letter to the SEC with a draftOct 31, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedOct 31, 2023Offer documentSEC
UPLOAD · Letter from the SECOct 18, 2023Other filingsSEC
SEC STAFF LETTEROct 13, 2023Other filingsSEC
DRSLTR · Letter to the SEC with a draftOct 4, 2023Other filingsSEC
DRS/A · Draft registration statement, amendedOct 4, 2023Offer documentSEC
UPLOAD · Letter from the SECSep 27, 2023Other filingsSEC
DRS · Draft registration statementAug 25, 2023Offer documentSEC
DDec 29, 2022Other filingsSEC
D/AFeb 14, 2022Other filingsSEC
DJun 23, 2021Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from ArriVent BioPharma, Inc.’s releases · as of Nov 5, 2026

Common shares
51,723,074
Fully diluted
51,723,074

Fully diluted

LineSharesAs of
Common shares51,723,074Nov 5, 2026

Share count over time

CountShares
Nov 5, 202651,723,074
Sep 30, 202651,212,170

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Montanova Capital, LLC4.93M9.5%US$149MSep 30, 2026
Infinitum Asset Management, LLC4.52M8.7%US$137MSep 30, 2026
Hhlr Advisors, LTD.3.93M7.6%US$119MSep 30, 2026
BlackRock3.41M6.6%US$103MSep 30, 2026
Orbimed Advisors LLC3.03M5.9%US$91.7MSep 30, 2026
Fidelity2.97M5.7%US$89.8MSep 30, 2026
Vanguard2.74M5.3%US$83.1MSep 30, 2026
Octagon Capital Advisors LP2.14M4.1%US$64.8MSep 30, 2026
Vivo Capital, LLC1.79M3.5%US$54.1MSep 30, 2026
State Street1.76M3.4%US$53.4MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Sofinnova Investments, Inc.1.7M3.3%US$51.4MSep 30, 2026
General Catalyst Group Management, LLC1.49M2.9%US$45.3MSep 30, 2026
Logos Global Management LP1.35M2.6%US$40.9MSep 30, 2026
Novo Holdings A/S1.18M2.3%US$35.6MSep 30, 2026
Goldman Sachs1.11M2.1%US$33.5MSep 30, 2026
Bank of America1.07M2.1%US$32.4MSep 30, 2026
Geode Capital1.06M2.0%US$32MSep 30, 2026
D. E. Shaw & Co., Inc.908K1.8%US$27.5MSep 30, 2026
Adage Capital Partners Gp, L.L.C.686K1.3%US$20.8MSep 30, 2026
HSG Holding Ltd663K1.3%US$20.1MSep 30, 2026
UBS569K1.1%US$17.2MSep 30, 2026
Millennium509K0.98%US$15.4MSep 30, 2026
Balyasny Asset Management L.P.503K0.97%US$15.2MSep 30, 2026
Point72 Asset Management, L.P.493K0.95%US$14.9MSep 30, 2026
Foresite Capital Management VI LLC490K0.95%US$14.8MSep 30, 2026
Seven Fleet Capital Management LP451K0.87%US$13.7MSep 30, 2026
Schwab366K0.71%US$11.1MSep 30, 2026
Northern Trust349K0.67%US$10.6MSep 30, 2026
Dimensional325K0.63%US$9.84MSep 30, 2026
Ameriprise313K0.61%US$9.48MSep 30, 2026
E Fund Management Co., Ltd.278K0.54%US$8.41MSep 30, 2026
Acuta Capital Partners, LLC171K0.33%US$5.17MSep 30, 2026
Morgan Stanley167K0.32%US$5.06MSep 30, 2026
Woodline Partners LP153K0.30%US$4.64MSep 30, 2026
Wellington134K0.26%US$4.05MSep 30, 2026
Trexquant Investment LP119K0.23%US$3.61MSep 30, 2026
Algert Global LLC108K0.21%US$3.26MSep 30, 2026
Nomura105K0.20%US$3.18MSep 30, 2026
BNY103K0.20%US$3.13MSep 30, 2026
Nuveen102K0.20%US$3.09MSep 30, 2026
KVP Capital Advisors, LP102K0.20%US$3.09MSep 30, 2026
SummitTX Capital, L.P.102K0.20%US$3.09MSep 30, 2026
Affinity Asset Advisors, LLC100K0.19%US$3.03MSep 30, 2026
Vestal Point Capital, LP100K0.19%US$3.03MSep 30, 2026
Hrt Financial LP94,6540.18%US$2.87MSep 30, 2026
Sectoral Asset Management Inc87,3430.17%US$2.64MSep 30, 2026
Barclays82,4520.16%US$2.5MSep 30, 2026
Jump Financial, LLC81,0670.16%US$2.45MSep 30, 2026
Squarepoint Ops LLC73,1410.14%US$2.21MSep 30, 2026
Assenagon Asset Management S.A.67,0950.13%US$2.03MSep 30, 2026

This page holds 50 of 146 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Select Biotechnology Portfolio1.44M2.8%US$43.6MMay 31, 2026
Vanguard Total Stock Market Index Fund1.34M2.6%US$46.5MJun 30, 2026
iShares Russell 2000 ETF985K1.9%US$34.2MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF880K1.7%US$30.6MJun 30, 2026
Fidelity Small Cap Index Fund415K0.80%US$12.4MJul 31, 2026
Vanguard Extended Market Index Fund397K0.77%US$13.8MJun 30, 2026
iShares Russell 2000 Growth ETF350K0.68%US$12.2MJun 30, 2026
Fidelity Growth Company Fund324K0.63%US$9.81MMay 31, 2026
Fidelity Small Cap Growth Fund299K0.58%US$8.91MJul 31, 2026
iShares Biotechnology ETF230K0.45%US$8.01MJun 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Vanguard Russell 2000 Index Fund166K0.32%US$5.02MMay 31, 2026
Fidelity Extended Market Index Fund158K0.31%US$4.79MMay 31, 2026
Fidelity Small Cap Growth K6 Fund149K0.29%US$4.44MJul 31, 2026
Schwab U.S. Small-Cap ETF147K0.28%US$4.45MMay 31, 2026
iShares Micro-Cap ETF127K0.25%US$4.41MJun 30, 2026
Schwab Small-Cap Index Fund92,0660.18%US$2.75MJul 31, 2026
Fidelity Growth Company K6 Fund90,3350.17%US$2.73MMay 31, 2026
Goldman Sachs Small Cap Equity Insights Fund87,6440.17%US$2.61MJul 31, 2026
Fidelity Series Growth Company Fund69,5000.13%US$2.1MMay 31, 2026
Master Small Cap Index Series67,4050.13%US$2.34MJun 30, 2026
Vanguard Health Care Index Fund62,6260.12%US$1.9MMay 31, 2026
Fidelity Total Market Index Fund59,3610.11%US$1.8MMay 31, 2026
Dimensional U.S. Small Cap ETF55,8580.11%US$1.67MJul 31, 2026
U.S. Micro Cap Portfolio50,2980.10%US$1.5MJul 31, 2026
Nuveen Small Cap Blend Index Fund50,2780.10%US$1.5MJul 31, 2026
iShares Core S&P Total U.S. Stock Market ETF49,0750.09%US$1.7MJun 30, 2026
Fidelity Series Total Market Index Fund46,7510.09%US$1.42MMay 31, 2026
ALPS Medical Breakthroughs ETF45,5630.09%US$1.38MMay 31, 2026
Tema Oncology ETF42,7440.08%US$1.29MMay 31, 2026
EQ/2000 Managed Volatility Portfolio41,1150.08%US$1.43MJun 30, 2026
U.S. Small Cap Portfolio36,7140.07%US$1.09MJul 31, 2026
Fidelity Small Cap Growth Index Fund35,5310.07%US$1.23MJun 30, 2026
Goldman Sachs Small Cap Growth Insights Fund35,0850.07%US$1.05MJul 31, 2026
Vanguard Russell 2000 Growth Index Fund30,4390.06%US$921KMay 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares29,8030.06%US$889KJul 31, 2026
Fidelity Nasdaq Composite Index Fund27,0560.05%US$819KMay 31, 2026
LVIP State Street Small-Cap Index Fund26,9000.05%US$935KJun 30, 2026
Nuveen Equity Index Fund24,8570.05%US$741KJul 31, 2026
Fidelity Nasdaq Composite Index ETF22,8390.04%US$691KMay 31, 2026
EQ/Small Company Index Portfolio22,4700.04%US$781KJun 30, 2026
Goldman Sachs Small Cap Value Insights Fund21,0910.04%US$629KJul 31, 2026
Schwab Total Stock Market Index Fund20,2690.04%US$604KJul 31, 2026
Vanguard Balanced Index Fund19,8740.04%US$690KJun 30, 2026
Fidelity ZERO Total Market Index Fund19,5970.04%US$584KJul 31, 2026
Vanguard Institutional Total Stock Market Index Fund19,2810.04%US$670KJun 30, 2026
Small Cap Index Fund19,0560.04%US$662KJun 30, 2026
Optimize Strategy Index ETF18,8510.04%US$655KJun 30, 2026
Global X Russell 2000 ETF18,1200.04%US$540KJul 31, 2026
Schwab U.S. Broad Market ETF18,0080.03%US$545KMay 31, 2026
EQ/AB Small Cap Growth Portfolio17,6100.03%US$612KJun 30, 2026

This page holds 50 of 144 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
Infinitum Asset Management, LLC9.90%4.12MDec 31, 2025Schedule 13G
Montanova Capital, LLC9.90%3.41MJun 30, 2025Schedule 13G
Hillhouse Investment Management, Ltd.9.50%3.93MDec 31, 2025Schedule 13G
BlackRock, Inc.6.80%3.18MJun 30, 2026Schedule 13G
FMR LLC5.80%2.86MSep 30, 2026Schedule 13G
ORBIMED ADVISORS LLC5.80%2.88MOct 6, 2026Schedule 13D
HBM Healthcare Investments (Cayman) Ltd.5.40%2.2MOct 8, 2025Schedule 13G
Vivo Opportunity, LLC5.00%2.47MOct 6, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James Healy
Other companies: Seaport Therapeutics, Inc. (Director · Since at least Apr 30, 2026); BioAge Labs, Inc. (Director · Since at least Sep 25, 2024); Rapport Therapeutics, Inc. (Director · Since at least Jun 6, 2024); Y mAbs Therapeutics (Director · Since at least Jun 12, 2019); CinCor Pharma Inc (Director · Jan 6, 2022 – Nov 28, 2022 · Past); Bolt Biotherapeutics, Inc. (Director · Feb 4, 2021 – Jun 12, 2024 · Past); Karuna Therapeutics Inc (Director · Jun 27, 2019 – Mar 18, 2024 · Past); Coherus Oncology, Inc. (Director · May 22, 2019 – Jan 7, 2022 · Past); Natera, Inc. (Director · Sep 14, 2018 – Apr 25, 2025 · Past)
Director · Since at least Jan 25, 2024
John Hohneker
Other companies: Curis, Inc. (Director · Since at least Dec 2, 2021); Carisma Therapeutics, Inc. (Director · Apr 1, 2024 – Jun 26, 2024 · Past); Humanigen Inc (Director · Oct 19, 2021 – Jul 27, 2022 · Past); Aravive Inc (Director · May 12, 2021 – Sep 23, 2022 · Past); Evelo Biosciences, Inc. (Director · Jan 27, 2021 – Jun 8, 2023 · Past); Dimension Therapeutics (Director · Jan 18, 2017 – Nov 7, 2017 · Past)
Director · Since at least May 16, 2024
Zhengbin Yao
Other companies: Alumis Inc. (Director · Since at least Jun 27, 2024); NexImmune, Inc. (Director · Feb 11, 2021 – Jul 5, 2023 · Past); Viela Bio Inc (Chief Executive Officer, Director · Oct 2, 2019 – Mar 13, 2021 · Past); Tanox Inc (Vice President of Research · Feb 15, 2006 – Nov 20, 2006 · Past)
Chairman, Chief Executive Officer · Since at least Jan 25, 2024
Bahija Jallal
Other companies: Immunocore Holdings plc (Chief Executive Officer · Since at least Jan 2, 2024); Elevance Health, Inc. (Director · Since at least Feb 1, 2018); Guardant Health, Inc. (Director · Apr 17, 2019 – Jun 15, 2022 · Past)
Director · Jan 25, 2024 – Jan 25, 2024 · Past
Kristine Peterson
Other companies: Mineralys Therapeutics, Inc. (Director · Since at least Oct 19, 2026); Enanta Pharmaceuticals, Inc. (Director · Since at least Mar 11, 2026); Immunocore Holdings plc (Non-Executive Director · Since at least May 15, 2025)
Lead Independent Director · Since at least Jun 18, 2025
Winston Kung
Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Since at least Aug 16, 2024); Janux Therapeutics, Inc. (Director · Since at least Sep 21, 2022); PMV Pharmaceuticals, Inc. (COO, CFO · Sep 24, 2020 – May 12, 2023 · Past)
Chief Financial Officer · Since at least Jan 25, 2024
James Kastenmayer
Other companies: Spyre Therapeutics, Inc. (General Counsel · Aug 23, 2022 – Feb 23, 2023 · Past); Viela Bio Inc (General Counsel · Jan 6, 2020 – Mar 15, 2021 · Past)
General Counsel · Since at least Jan 25, 2024
Brent RiceChief Commercial Officer · Since at least Nov 10, 2025
Chris NoletDirector · Since at least Nov 4, 2026
Merdad ParseyDirector · Since at least May 12, 2025
All 13 people
PersonSeat
Robin LaChapelleChief Operating Officer · Since at least Jan 25, 2024
Stuart LutzkerDirector · Since at least Jan 25, 2024
Yang WangChief Technology Officer · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about ArriVent BioPharma, Inc.